<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655822</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-444-001</org_study_id>
    <nct_id>NCT02655822</nct_id>
  </id_info>
  <brief_title>Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers</brief_title>
  <official_title>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corvus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Corvus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral&#xD;
      small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the&#xD;
      immune system. This trial will study the safety, tolerability, and anti-tumor activity of&#xD;
      ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor&#xD;
      against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor.&#xD;
      Adenosine suppresses the anti-tumor activity of T cells and other immune cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral&#xD;
      small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the&#xD;
      immune system. This trial will study the safety, tolerability, and anti-tumor activity of&#xD;
      ciforadenant as a single agent and in combination with atezolizumab, an intravenous PD-L1&#xD;
      inhibitor. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine&#xD;
      suppresses the anti-tumor activity of T cells and other immune cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">July 2021</completion_date>
  <primary_completion_date type="Actual">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs) of ciforadenant as a single agent and in combination with atezolizumab</measure>
    <time_frame>28 days following first administration of ciforadenant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate per RECIST v1.1 criteria of ciforadenant as a single agent and in combination with atezolizumab</measure>
    <time_frame>From start of treatment to end of treatment, up to 72 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.4.03, of ciforadenant as a single agent and in combination with atezolizumab</measure>
    <time_frame>Continuously, up to 72 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean and median Area under the curve (AUC) of ciforadenant</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean and median Maximum concentration (Cmax) of ciforadenant</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify the MDL (maximum dose level) of single agent ciforadenant</measure>
    <time_frame>From start of treatment to end of treatment, up to 72 months.</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">502</enrollment>
  <condition>Renal Cell Cancer</condition>
  <condition>Metastatic Castration Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciforadenant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciforadenant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciforadenant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciforadenant + atezolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 - Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciforadenant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciforadenant</intervention_name>
    <description>100 mg orally twice daily for the first 14 days of each 28-day cycle.</description>
    <arm_group_label>Cohort 1 - Closed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciforadenant</intervention_name>
    <description>100 mg orally twice daily for 28 days of each 28-day cycle.</description>
    <arm_group_label>Cohort 2 - Closed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciforadenant</intervention_name>
    <description>200 mg orally once daily for the first 14 days of each 28-day cycle.</description>
    <arm_group_label>Cohort 3 - Closed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciforadenant + atezolizumab</intervention_name>
    <description>Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciforadenant</intervention_name>
    <description>Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.</description>
    <arm_group_label>Cohort 5 - Closed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Renal Cell Carcinoma Inclusion Criteria&#xD;
&#xD;
          1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.&#xD;
&#xD;
          2. Documented pathologic diagnosis of clear cell RCC.&#xD;
&#xD;
          3. Relapsed or refractory to 1-2 prior lines of therapy containing at least an&#xD;
             anti-PD-(L)1 agent.&#xD;
&#xD;
          4. Measurable disease according to RECIST v1.1&#xD;
&#xD;
          5. Mandatory newly collected tumor biopsy sample obtained prior to treatment initiation.&#xD;
&#xD;
        Renal Cell Carcinoma Exclusion Criteria&#xD;
&#xD;
          1. History of severe hypersensitivity reaction to monoclonal antibodies.&#xD;
&#xD;
          2. Has immunodeficiency or requires treatment with systemic immunosuppressive medication&#xD;
             within 2 weeks prior to initiation of study treatment or anticipation of need for&#xD;
             systemic immunosuppressant medication during study treatment.&#xD;
&#xD;
          3. Has an active autoimmune disease requiring systemic treatment with in the past 2 years&#xD;
             OR a documented history of clinically severe autoimmune disease.&#xD;
&#xD;
        Metastatic Castration-Resistant Prostate Cancer Inclusion Criteria&#xD;
&#xD;
          1. Documentation of disease: progressive CRPC with histologically or cytologically&#xD;
             confirmed adenocarcinoma of the prostate.&#xD;
&#xD;
          2. Patients must have radiologically evident metastatic disease, but it can be measurable&#xD;
             or non-measurable disease:&#xD;
&#xD;
               -  Measurable disease: nodal, visceral, or extra nodal lesions according to RECIST&#xD;
                  v1.1 using a diagnostic computed tomography&#xD;
&#xD;
               -  Non-measurable disease: bone only disease (up to 1/3 of study population) per&#xD;
                  PCWG3 criteria&#xD;
&#xD;
          3. 1-3 prior lines of therapy, including at least one newer generation androgen synthesis&#xD;
             inhibitor (e.g., abiraterone) or androgen receptor antagonist (e.g., enzalutamide,&#xD;
             apalutamide, darolutamide).&#xD;
&#xD;
          4. Mandatory newly collected tumor biopsy sample obtained prior to treatment initiation.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.&#xD;
&#xD;
        Metastatic Castration-Resistant Prostate Cancer Exclusion Criteria&#xD;
&#xD;
          1. Has pure small-cell histology and variants with predominant (â‰¥ 50%) neuroendocrine&#xD;
             differentiation.&#xD;
&#xD;
          2. Has a history of severe hypersensitivity reaction to monoclonal antibodies.&#xD;
&#xD;
          3. Has immunodeficiency or requires treatment with systemic immunosuppressive medication&#xD;
             within 2 weeks prior to initiation of study treatment or anticipation of need for&#xD;
             systemic immunosuppressant medication during study treatment.&#xD;
&#xD;
          4. Has an active autoimmune disease requiring systemic treatment with in the past 2 years&#xD;
             OR a documented history of clinically severe autoimmune disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehrdad Mobasher, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Corvus Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RCC</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>mCRPC</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

